Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
FATE Presents Encourgaing Data From Lupus Study, Stock Gains Zacks Investment Research - Tue Nov 19, 2:10PM CST

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 32.50 (+0.25%)
CSTL : 29.11 (+2.32%)
FATE : 2.07 (-6.76%)
SPRO : 1.1600 (-3.33%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis Quiver Quantitative, Inc. - Mon Nov 18, 5:20PM CST

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 2.07 (-6.76%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence GlobeNewswire - Mon Nov 18, 7:05AM CST

FATE : 2.07 (-6.76%)
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence GlobeNewswire - Mon Nov 18, 7:00AM CST

FATE : 2.07 (-6.76%)
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus Zacks Investment Research - Wed Nov 13, 11:26AM CST

Fate Therapeutics FATE reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents. The company reported a loss of 46 cents per...

IMCR : 32.50 (+0.25%)
CSTL : 29.11 (+2.32%)
ANIP : 55.90 (+1.45%)
FATE : 2.07 (-6.76%)
Fate Therapeutics: Q3 Earnings Snapshot AP - Tue Nov 12, 3:18PM CST

Fate Therapeutics: Q3 Earnings Snapshot

FATE : 2.07 (-6.76%)
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates GlobeNewswire - Tue Nov 12, 3:01PM CST

FATE : 2.07 (-6.76%)
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting GlobeNewswire - Sat Nov 9, 12:30PM CST

FATE : 2.07 (-6.76%)
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting GlobeNewswire - Fri Nov 8, 3:01PM CST

FATE : 2.07 (-6.76%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Nov 4, 3:01PM CST

FATE : 2.07 (-6.76%)

Barchart Exclusives

1 EV Stock Under $10 With 25% Upside Potential Barchart - 1 hour ago
This charging stock has been under heavy pressure lately amid concerns over the fate of EV tax credits. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot